as a sales agent for Daiichi Sankyo Inc

Morla is a shot in the dark on his athleticism: a raw international signing with 4.52 ERA through three pro seasons of A- and Rookie ball. Meanwhile, Miles and Fox are both likely to have some influence on the A's next year. Expect Miles to take over where Crosby left off as a mostly anemic backup infielder. Miles has hit as well as .317 in 2007 with the Cardinals, but it was a very hollow .317 accompanied by a .398 SLG. He's coming off of a miserable season in which he hit for a measly .185 batting average with an OPS of...drum roll please...466.In other words, far worse than Crosby's '09 campaign (652).I'd expect him to neither match what he did the Cardinals nor repeat his embarrassing '09 campaign. putting him as a higher average, lower slugging, Bobby Crosby replacement.Jake Fox is probably the most valuable player involved in this five-player trade. That's not saying a ton, but Fox does have the best minor league numbers of the pack, sporting a minor league OPS of 885 and a major league OPS of 762.That's significant for the A's.

The only problem with Fox is that he's best suited to play catcher. The A's unquestionably intend to use him at third base, but if he doesn't excel there, he'll be competing for a job as backup catcher or at first base Overall, not a bad trade. We lost some expendable pitching, and a decent outfield prospect who we didn't really need for two decent stop-gap infielders I approve.. New office will provide marketing support to improve awareness and knowledgeof Daiichi Sankyo's innovative treatmentsPARSIPPANY, N.J., Jan. 7 /PRNewswire/ Daiichi Sankyo, Inc., announced todaythat it has established a subsidiary Daiichi Sankyo de Puerto Rico, Inc Daiichi Sankyo de Puerto Rico, Inc. is based in San Juan, and led by JoseVazquez, Regional Director Puerto Rico, who has more than 20 years ofexperience in pharmaceutical sales and marketing. Vazquez, who earned hisBachelor of Arts degree in Biology and Juris Doctor from the University ofPuerto Rico, has assembled an experienced team of sales representatives andmarketing professionals with many years of experience and deep knowledge ofthe local market in Puerto Rico.

"We are excited about the opening of this new office in Puerto Rico. Ourpresence here enables us to establish close ties with healthcare partnersthroughout Puerto Rico and to directly support our customers with educationalmaterials and managed care programs," said Vazquez. "The opening of thisoffice is another indication of the growth of Daiichi Sankyo, which is fueledby our expanding portfolio of marketed products, as well as by our robustpipeline of promising new compounds. The new office in San Juan will ensurethat our Puerto Rico customers have direct access to information about theseinnovative products." Daiichi Sankyo de Puerto Rico, Inc., as a sales agent for Daiichi Sankyo, Inc.in Puerto Rico, will provide the local medical community and their patientsdirect access to materials and information about Daiichi Sankyo, Inc.'sproducts that address medical needs in cardiovascular and diabetes care.Daiichi Sankyo's current portfolio of marketed products is focused onhypertension, cholesterol and type 2 diabetes. The current focus of DaiichiSankyo's research and development is cardiovascular and metabolic disease,including therapies for dyslipidemia, hypertension, diabetes and acutecoronary syndrome. Daiichi Sankyo is also pursuing the discovery of newmedicines in the areas of thrombosis, cancer, diabetes, and autoimmunedisease/rheumatoid arthritis.The new Daiichi Sankyo de Puerto Rico, Inc. office is located at The AtriumOffice Center, 530 Avenida de la Constitucion, Office Number 258, Puerta deTierra, San Juan, Puerto Rico 00901-2304.